marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-31-2024
Alnylam Pharmaceuticals Financial Ratios 2011-2024 | ALNY
Annual Financial Ratios Alnylam Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-42.3 | -21.0 | -21.9 | -19.8 | -14.2 | -10.8 | -24.2 | -7.7 | -20.0 | -19.3 | -59.3 | -11.3 | -8.2 |
P/S |
10.2 | 22.9 | 22.1 | 34.6 | 57.4 | 109.7 | 132.2 | 66.9 | 140.9 | 137.8 | 112.1 | 17.9 | 5.7 |
EPS |
-3.5 | -9.3 | -7.2 | -7.5 | -8.1 | -7.6 | -5.4 | -4.8 | -3.5 | -4.8 | -1.4 | -2.1 | -1.4 |
EV (Enterprise Value) |
21.9 B | 26.6 B | 20.9 B | 18.9 B | 13 B | 8.07 B | 11.5 B | 3.31 B | 5.73 B | 7.04 B | 5.38 B | 1.3 B | 567 M |
EBITDA per Share |
-1.83 | -6.09 | -5.58 | -6.9 | -8.1 | -8.03 | -5.37 | -4.78 | -3.3 | -2.32 | -1.34 | -1.08 | -1.17 |
EV/EBITDA |
-31.5 | -22.5 | -13.6 | -9.7 | -23.2 | -7.6 | -20.3 | -40.0 | -63.3 | -21.0 | -8.1 | ||
PEG |
2.25 | -4.12 | -3.82 | -1.07 | 2.0 | 0.27 | 1.84 | 0.2 | -0.69 | 0.08 | -1.89 | 0.2 | 0.27 |
P/B |
-84.5 | -150.0 | 31.8 | 16.8 | 8.8 | 6.3 | 6.7 | 3.4 | 4.6 | 7.4 | 19.6 | 8.9 | 4.0 |
P/CF |
178.9 | -43.8 | -29.1 | -27.7 | -30.1 | -11.9 | -24.4 | -8.5 | -28.7 | -39.9 | -72.8 | -9.7 | -5.4 |
ROE % |
199.53 | 714.91 | -144.99 | -84.46 | -61.59 | -58.49 | -27.79 | -44.57 | -22.94 | -38.49 | -33.00 | -79.08 | -48.86 |
ROA % |
-11.49 | -31.90 | -23.41 | -25.19 | -37.00 | -48.36 | -24.61 | -32.48 | -20.92 | -33.38 | -21.22 | -36.87 | -20.45 |
ROCE % |
127.89 | 496.18 | -120.48 | -81.52 | -45.99 | -58.39 | -27.02 | -37.54 | -22.35 | -18.72 | -25.35 | -26.58 | -27.28 |
Current Ratio |
0.9 | 1.0 | 1.2 | 1.4 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | 4.7 | 2.6 | 1.9 |
DSO |
13.2 | 18.6 | 23.1 | 17.9 | 71.4 | 91.4 | 138.0 | 180.6 | 73.7 | 288.3 | 32.9 | 0.6 | 6.5 |
DIO |
148.4 | 280.3 | 256.4 | 323.6 | 820.6 | 4875.0 | - | - | - | - | - | - | - |
DPO |
104.5 | 223.3 | 199.0 | 250.6 | 726.5 | 12094.0 | - | - | - | - | - | - | - |
Operating Cycle |
161.6 | 298.9 | 279.5 | 341.6 | 892.1 | 4966.4 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
57.0 | 75.6 | 80.5 | 91.0 | 165.6 | -7127.6 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Alnylam Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.87 | -0.13 | -0.52 | - | 1.18 | -2.21 | -1.4 | - | -3.32 | -2.29 | -2 | - | -1.72 | -1.61 | -1.71 | -2.09 | -2.18 | -1.56 | -1.62 | -2.47 | -1.92 | -2.02 | -1.73 | -2.09 | -2.43 | -1.63 | -1.41 | -1.48 | -1.34 | -1.34 | -1.25 | -1.32 | -1.21 | -1.05 | -1.21 | -1.07 | -0.91 | -0.85 | -0.62 | -0.28 | -0.58 | -0.58 | -3.7 | -0.51 | -0.48 | -0.29 | -0.15 | -1.2 | -0.38 | -0.25 | -0.25 | -0.33 | -0.31 | -0.33 | -0.38 |
EBITDA per Share |
- | - | -0.24 | - | - | - | -1.09 | - | -1.87 | -1.59 | -1.14 | - | -1.22 | -1.24 | -1.48 | - | -1.73 | -1.59 | -1.8 | - | -1.88 | -2.11 | -1.75 | - | -2.47 | -1.86 | -1.44 | - | -1.26 | -1.3 | -1.2 | - | -1.1 | -0.98 | -1.24 | - | -0.76 | -0.76 | -0.59 | - | -0.48 | -0.52 | -3.93 | - | -0.39 | -0.27 | -0.13 | - | -0.22 | -0.14 | -0.19 | - | -0.2 | -0.25 | -0.34 |
ROE % |
146.82 | 402.58 | -80.46 | 45.71 | 645.85 | 1335.06 | 1109.85 | 382.65 | 355.59 | -271.60 | -136.24 | -70.89 | -94.86 | -92.73 | -88.15 | -84.46 | -79.69 | -69.26 | -66.88 | -61.59 | -58.63 | -62.98 | -60.29 | -58.49 | -50.30 | -38.42 | -32.56 | -27.79 | -32.01 | -36.36 | -39.45 | -44.57 | -39.47 | -34.23 | -30.11 | -22.94 | -18.05 | -16.67 | -15.71 | -38.49 | -48.18 | -54.46 | -56.47 | -33.00 | -67.43 | -70.99 | -73.94 | -79.08 | -44.81 | -41.48 | -43.54 | -48.86 | -11.22 | -11.72 | -13.80 |
ROA % |
-0.95 | 5.55 | -2.14 | -9.40 | -20.88 | -36.21 | -35.10 | -25.48 | -31.37 | -18.78 | -24.18 | -17.44 | -24.59 | -26.14 | -26.00 | -25.19 | -29.57 | -30.85 | -34.75 | -37.00 | -38.89 | -45.76 | -46.98 | -48.36 | -42.06 | -32.65 | -28.20 | -24.61 | -26.42 | -28.50 | -29.70 | -32.48 | -30.08 | -27.37 | -25.41 | -20.92 | -16.36 | -14.90 | -13.80 | -33.38 | -39.10 | -42.08 | -42.32 | -21.22 | -35.15 | -34.88 | -35.06 | -36.87 | -20.32 | -18.23 | -18.63 | -20.45 | -4.70 | -4.90 | -5.78 |
ROCE % |
-1931.90 | -1823.14 | -181.76 | -14.84 | 366.66 | 877.10 | 711.90 | 236.04 | 212.00 | -193.53 | -101.77 | -61.27 | -83.43 | -81.56 | -84.00 | -62.41 | -77.44 | -70.32 | -67.17 | -44.58 | -64.13 | -68.65 | -67.00 | -45.65 | -52.77 | -40.34 | -32.39 | -19.97 | -31.56 | -36.03 | -39.26 | -33.60 | -39.79 | -34.39 | -30.11 | -16.09 | -20.92 | -19.55 | -18.59 | -38.37 | -50.30 | -57.39 | -60.47 | -23.43 | -36.97 | -38.58 | -39.70 | -30.66 | -41.21 | -38.21 | -40.33 | -34.94 | -10.54 | -11.12 | -13.29 |
Current Ratio |
1.0 | 1.0 | 0.9 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.0 | - | 1.1 | 1.2 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 2.5 | 2.5 | 2.5 | 2.5 | 5.8 | 5.8 | 5.8 | 5.8 | 8.7 | 8.7 | 8.7 | 8.7 | 3.7 | 3.7 | 3.7 | 3.7 | 11.4 | 11.4 | 11.4 | 11.4 | 7.5 | 7.5 | 7.5 | 7.5 | 2.8 | 2.8 | 2.8 | 2.8 | 1.9 | 1.9 | 1.9 | 1.9 | 1.7 | 1.7 | 1.7 | 1.7 |
DSO |
60.4 | 43.6 | 59.9 | - | 33.2 | 63.0 | 65.4 | - | 3.8 | 4.8 | 20.7 | - | 14.0 | 11.0 | 13.5 | 18.7 | 24.3 | 29.4 | 22.2 | 19.0 | 19.4 | 30.5 | 28.2 | 24.4 | 248.1 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | - |
DIO |
89.0 | 120.7 | 153.0 | - | 112.7 | 140.7 | 287.2 | - | 144.3 | 105.2 | 320.7 | - | 296.0 | 238.7 | 295.6 | - | 329.5 | 375.7 | 451.2 | - | 986.3 | 1188.6 | 1096.2 | - | 16030.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
80.6 | 103.2 | 111.7 | - | 76.7 | 73.9 | 176.6 | - | 50.7 | 73.6 | 249.6 | - | 151.3 | 148.5 | 192.9 | - | 227.7 | 259.6 | 349.3 | - | 873.2 | 1052.2 | 1493.9 | - | 39769.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
149.4 | 164.3 | 212.9 | - | 145.8 | 203.7 | 352.6 | - | 148.1 | 110.0 | 341.4 | - | 310.0 | 249.7 | 309.1 | 18.7 | 353.8 | 405.1 | 473.4 | 19.0 | 1005.8 | 1219.0 | 1124.4 | 24.4 | 16278.8 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | - |
Cash Conversion Cycle |
68.9 | 61.1 | 101.2 | - | 69.2 | 129.8 | 176.0 | - | 97.4 | 36.4 | 91.8 | - | 158.8 | 101.2 | 116.2 | 18.7 | 126.1 | 145.5 | 124.1 | 19.0 | 132.6 | 166.8 | -369.6 | 24.4 | -23490.2 | 17.2 | 82.6 | 58.5 | 80.2 | 141.5 | 138.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.9 | -8.3 | -80.7 | - | -286.8 | -132.4 | - |
All numbers in USD currency